Higher-dose Exelon Patch approved for Alzheimer's

Share this article:
Higher-dose Exelon Patch approved for Alzheimer's
Higher-dose Exelon Patch approved for Alzheimer's
The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer's disease. Approval was based on a 48-week double-blind phase of the OPTIMA study. The controlled trial targeted people with mild to moderate Alzheimer's. Compared to an older patch, patients treated with this higher dosage patch experienced statistically significant functional improvement.
Share this article:

More in Products

Bertlesmann buys Relias Learning

Bertelsmann, a media company based in Germany, said last week it is buying Relias Learning from its current owners, Vista Equity Partners and LLR Partners.

Acuity Brands introduces LED collection

Acuity Brands introduces LED collection

Acuity Brands says its new CanoeTM LED Pendant and Sconce Collection from Winona Lighting® can meet the needs of designers in unique spaces.

SwimEx debuts Triton Pool

SwimEx debuts Triton Pool

SwimEx Inc. has announced the Triton, the newest member of its line of fitness and therapy pools. It is available for the commercial and residential markets.